The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics

Clinical Psychopharmacology and Neuroscience

Volumn 11, Issue 2, 2013, Pages 80-88

  Ko, You Kyung ^a   Soh, Min Ah ^a   Kang, Shi Hyun ^a   Lee, Jong Il ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Antipsychotic agents; Dyslipidemias; Metabolic syndrome; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; RISK FACTOR; SCHIZOPHRENIA; SOUTH KOREA;

EID: 84883613998     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2013.11.2.80     Document Type: Article

References (31)

1. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36:239-245.
2. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-1349. (Pubitemid 38989085)
3. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607. (Pubitemid 19004941)
4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553. (Pubitemid 28319935)
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
6. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. [cited 2005 Apr 14]. Available from http://www.idf.org/webdata/docs/IDF-Metasyndrome-definition.pdf.
7. Inoue S, Zimmet P, Caterson I, Chunming Chen, Ikeda Y, Khalid AK, et al. The Asia-Pacific perspective: redefining obesity and its treatment. Sidney:Health Communications Australia Pty Limit;2000.
8. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-272.
9. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32. (Pubitemid 41587460)
10. Araneta MR, Wingard DL, Barrett-Connor E. Type 2 diabetes and metabolic syndrome in Filipina-American women: a high-risk nonobese population. Diabetes Care 2002;25:494-499. (Pubitemid 41103342)
11. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220. (Pubitemid 29193917)
12. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696. (Pubitemid 29517559)
13. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363. (Pubitemid 29289721)
14. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(Suppl 7):22-31. (Pubitemid 32402182)
15. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273-281. (Pubitemid 32423994)
16. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566. (Pubitemid 34274937)
17. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000;157:975-981. (Pubitemid 30412350)
18. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-296. (Pubitemid 41110454)
19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S5-S20.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association;1994.
21. Kim D, Choi SY, Choi EK, Suh JW, Lee W, Kim YS, et al. Distribution of coronary artery calcification in an asymptomatic Korean population: association with risk factors of cardiovascular disease and metabolic syndrome. Korean Circ J 2008;38:29-35. (Pubitemid 351291594)
22. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689. (Pubitemid 32893993)
23. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care 2011;34:1323-1328.
24. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res 1998;6(Suppl 2):51S-209S.
25. Goldstein BJ. Insulin resistance: from benign to type 2 diabetes mellitus. Rev Cardiovasc Med 2003;4(Suppl 6):S3-S10. (Pubitemid 37526930)
26. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22. (Pubitemid 44234064)
27. Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001;58:565-572. (Pubitemid 32523736)
28. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583-2589. (Pubitemid 38766335)
29. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-2600. (Pubitemid 38766337)
30. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70:1-17. (Pubitemid 38916622)
31. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(Suppl 18):47-56.